Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly … Read more
Fennec Pharmaceuticals Inc (FENC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.333x
Based on the latest financial reports, Fennec Pharmaceuticals Inc (FENC) has a cash flow conversion efficiency ratio of -0.333x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.49 Million) by net assets ($-4.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Fennec Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Fennec Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Fennec Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fennec Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Avalue Technology
TWO:3479
|
-0.011x |
|
Hainan Yedao Group Co Ltd
SHG:600238
|
-0.076x |
|
ZYF Lopsking Aluminum Co Ltd
SHE:002333
|
0.000x |
|
Anora Group Oyj
HE:ANORA
|
0.266x |
|
INFUSYSTEMS HLDG.DL-0001
F:1TZ
|
N/A |
|
Modiv Inc
NYSE:MDV
|
0.020x |
|
Gaotu Techedu Inc
F:18WA
|
N/A |
|
Cahya Mata Sarawak Berhad
PINK:CHYMF
|
0.027x |
Annual Cash Flow Conversion Efficiency for Fennec Pharmaceuticals Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Fennec Pharmaceuticals Inc from 1999 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-5.87 Million | $26.98 Million | -4.595x | -411.49% |
| 2023-12-31 | $-11.62 Million | $-17.14 Million | 1.475x | -79.02% |
| 2022-12-31 | $-2.57 Million | $-18.06 Million | 7.029x | +879.53% |
| 2021-12-31 | $15.77 Million | $-14.22 Million | -0.902x | -68.09% |
| 2020-12-31 | $29.07 Million | $-15.60 Million | -0.536x | +29.69% |
| 2019-12-31 | $11.88 Million | $-9.06 Million | -0.763x | -107.78% |
| 2018-12-31 | $21.31 Million | $-7.83 Million | -0.367x | -169.84% |
| 2017-12-31 | $26.76 Million | $-3.64 Million | -0.136x | +77.13% |
| 2016-12-31 | $3.57 Million | $-2.12 Million | -0.595x | +82.49% |
| 2015-12-31 | $548.00K | $-1.86 Million | -3.398x | -22.59% |
| 2014-12-31 | $613.00K | $-1.70 Million | -2.772x | -282.48% |
| 2013-12-31 | $-1.46 Million | $-2.21 Million | 1.519x | +151.48% |
| 2012-12-31 | $-4.96 Million | $-2.99 Million | 0.604x | -97.75% |
| 2011-12-31 | $-120.00K | $-3.23 Million | 26.883x | +6765.85% |
| 2010-12-31 | $-4.92 Million | $-1.93 Million | 0.392x | +103.39% |
| 2009-12-31 | $406.00K | $-4.69 Million | -11.547x | -226.17% |
| 2008-12-31 | $3.05 Million | $-10.81 Million | -3.540x | -276.50% |
| 2007-12-31 | $14.15 Million | $-13.30 Million | -0.940x | +47.07% |
| 2006-12-31 | $7.58 Million | $-13.47 Million | -1.777x | -190.61% |
| 2005-12-31 | $20.06 Million | $-12.26 Million | -0.611x | -236.82% |
| 2003-12-31 | $33.00 Million | $-5.99 Million | -0.181x | +48.85% |
| 2002-12-31 | $15.31 Million | $-5.43 Million | -0.355x | +33.18% |
| 2001-12-31 | $6.08 Million | $-3.23 Million | -0.531x | -93.96% |
| 2000-12-31 | $9.82 Million | $-2.69 Million | -0.274x | +98.95% |
| 1999-12-31 | $46.73K | $-1.22 Million | -26.189x | -- |